A review of the epidemiological and clinical aspects of West Nile virus

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 193-203

  Gray, Timothy J ^a   Webb, Cameron E ^b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b Western Sydney Area Health Service   (Australia)

^c University of Sydney   (Australia)

Author keywords

Flavivirus; Mosquitoes; Public health threat

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; IMMUNOGLOBULIN; INSECT REPELLENT; RIBAVIRIN;

AGING; ALCOHOLISM; ASYMPTOMATIC DISEASE; CEREBROSPINAL FLUID ANALYSIS; CULEX; CULEX PIPIENS; DIABETES MELLITUS; DISEASE SURVEILLANCE; DRUG MEGADOSE; ECOLOGY; EPIDEMIC; EUROPE; FLAVIVIRUS; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGLOBULIN DEPOSITION; JAPANESE ENCEPHALITIS VIRUS; MUSCLE WEAKNESS; NEOPLASM; NONHUMAN; NORTH AMERICA; NUCLEIC ACID ANALYSIS; PASSIVE IMMUNIZATION; PHYLOGENY; REVIEW; SEROLOGY; SYMPTOMATOLOGY; VASCULARIZATION; VECTOR CONTROL; VIRUS GENOME; WEST NILE FEVER; WEST NILE FLAVIVIRUS; YELLOW FEVER;

EID: 84898913236     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S59902     Document Type: Review

References (134)

1. White DO, Fenner F. Medical Virology. 4th ed. San Diego, CA: Academic Press; 1994.
2. Deubel V, Fiette L, Gounon P, et al. Variations in biological features of West Nile viruses. Ann N Y Acad Sci. 2001; 951: 195-206.
3. De Madrid AT, Porterfield JS. The flaviviruses (group B arboviruses): a cross-neutralization study. J Gen Virol. 1974; 23(1): 91-96.
4. May FJ, Davis CT, Tesh RB, Barrett AD. Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol. 2011; 85(6): 2964-2974.
5. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg. 1940; 20: 471-472.
6. Melnick JL, Paul JR, Riordan JT, Barnett VH, Goldblum N, Zabin E. Isolation from human sera in Egypt of a virus apparently identical to West Nile virus. Proc Soc Exp Biol Med. 1951; 77(4): 661-665.
7. Bernkopf H, Levine S, Nerson R. Isolation of West Nile virus in Israel. J Infect Dis. 1953; 93(3): 207-218.
8. Hurlbut HS, Rizk F, Taylor RM, Work TH. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg. 1956; 5(4): 579-620.
9. Murgue B, Murri S, Zientara S, Durand B, Durand JP, Zeller H. West Nile outbreak in horses in southern France, 2000: the return after 35 years. Emerg Infect Dis. 2001; 7(4): 692-696.
10. Joubert L, Oudar J, Hannoun C, et al. [Epidemiology of the West Nile virus: study of a focus in Camargue. IV. Meningo-encephalomyelitis of the horse]. Ann Inst Pasteur (Paris). 1970; 118(2): 239-247. French.
11. Sejvar JJ. West Nile virus: an historical overview. Ochsner J. 2003; 5(3): 6-10.
12. Jupp PG, Blackburn NK, Thompson DL, Meenehan GM. Sindbis and West Nile virus infections in the Witwatersrand-Pretoria region. S Afr Med J. 1986; 70(4): 218-220.
13. Hubálek Z, Halouzka J. West Nile fever-a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis. 1999; 5(5): 643-650.
14. Heinz F, Collett MS, Purcell RH, et al. Family Flaviviridae. In: Van Regenmortel MH, Fauquet CM, Bishop DH, et al (editors). Virus taxonomy, Seventh report of the International Committee for the Taxonomy of Viruses. San Diego, CA: Academic Press; 2000; 859-878.
15. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet. 1998; 352(9130): 767-771.
16. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York city area in 1999. N Engl J Med. 2001; 344(24): 1807-1814.
17. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999; 286(5448): 2333-2337.
18. BC Centre for Disease Control. West Nile Virus Activity in British Columbia Surveillance Program Results 2012. Vancouver, BC: Provincial Health Services Authority; 2013.
19. Centers for Disease Control and Prevention (CDC). West Nile virus and other arboviral diseases-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(25): 513-517.
20. cdc. gov [homepage on the Internet]. West Nile virus disease cases and presumptive viremic blood donors by state-United States, 2013. Centers for Disease Control and Prevention; 2013 [updated January 7, 2014; cited December 30, 2013]. Available from: http://www. cdc. gov/westnile/statsMaps/preliminaryMapsData/. Accessed March 1, 2014.
21. phac-aspc. gc. ca [homepage on the Internet]. West Nile virus MONITOR-2013 human surveillance. Public Health Agency of Canada; 2013 [updated November 21, 2013; cited December 30, 2013]. Available from: http://www. phac-aspc. gc. ca/wnv-vwn/mon-hmnsurv-eng. php. Accessed March 1, 2014.
22. Pradier S, Lecollinet S, Leblond A. West Nile virus epidemiology and factors triggering change in its distribution in Europe. Rev Sci Tech. 2012; 31(3): 829-844.
23. Danis K, Papa A, Papanikolaou E, et al. Ongoing outbreak of West Nile virus infection in humans, Greece, July to Aug 2011. Euro Surveill. 2011; 16(34): 1-5.
24. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. Reporting on 2010 Surveillance Data and 2011 Epidemic Intelligence Data. Stockholm: European Centre for Disease Prevention and Control; 2013.
25. ecdc. europa. eu [homepage on internet]. Reported cases for West Nile fever for the EU and neighbouring countries: 2013. European Centre for Disease Prevention and Control; 2013 [cited December 30, 2013]. Available from: http://www. ecdc. europa. eu/en/healthtopics/west_nile_fever/west-nile-fever-maps/pages/index. aspx. Accessed March 20, 2014.
26. Papa A, Bakonyi T, Xanthopoulou K, Vázquez A, Tenorio A, Nowotny N. Genetic characterization of West Nile virus lineage 2, Greece, 2010. Emerg Infect Dis. 2011; 17(5): 920-922.
27. Balakrishnan A, Butte DK, Jadhav SM. Complete genome sequence of west nile virus isolated from alappuzha district, kerala, India. Genome Announc. 2013; 1(3): 1-2.
28. Gray TJ, Burrow JN, Markey PG, et al. West Nile virus (Kunjin subtype) disease in the northern territory of Australia-a case of encephalitis and review of all reported cases. Am J Trop Med Hyg. 2011; 85(5): 952-956.
29. Hall RA, Scherret JH, Mackenzie JS. Kunjin virus: an Australian variant of West Nile? Ann N Y Acad Sci. 2001; 951: 153-160.
30. Frost MJ, Zhang J, Edmonds JH, et al. Characterization of virulent West Nile virus Kunjin strain, Australia, 2011. Emerg Infect Dis. 2012; 18(5): 792-800.
31. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA. West Nile virus isolates from India: evidence for a distinct genetic lineage. J Gen Virol. 2007; 88(Pt 3): 875-884.
32. Bakonyi T, Ivanics E, Erdélyi K, et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006; 12(4): 618-623.
33. Bakonyi T, Hubálek Z, Rudolf I, Nowotny N. Novel flavivirus or new lineage of West Nile virus, central Europe. Emerg Infect Dis. 2005; 11(2): 225-231.
34. Barzon L, Papa A, Pacenti M, et al. Genome sequencing of West Nile Virus from human cases in Greece, 2012. Viruses. 2013; 5(9): 2311-2319.
35. Magurano F, Remoli ME, Baggieri M, et al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy. Clin Microbiol Infect. 2012; 18(12): E545-E547.
36. McMullen AR, Albayrak H, May FJ, Davis CT, Beasley DW, Barrett AD. Molecular evolution of lineage 2 West Nile virus. J Gen Virol. 2013; 94(Pt 2): 318-325.
37. Hubálek Z, Halouzka J, Juricová Z, Sebesta O. First isolation of mosquito-borne West Nile virus in the Czech Republic. Acta Virol. 1998; 42(2): 119-120.
38. Aliota MT, Jones SA, Dupuis AP, Ciota AT, Hubalek Z, Kramer LD. Characterization of Rabensburg virus, a flavivirus closely related to West Nile virus of the Japanese encephalitis antigenic group. PLoS One. 2012; 7(6): e39387.
39. Lvov DK, Butenko AM, Gromashevsky VL, et al. West Nile virus and other zoonotic viruses in Russia: examples of emerging-reemerging situations. Arch Virol Suppl. 2004; (18): 85-96.
40. Vazquez A, Sanchez-Seco MP, Ruiz S, et al. Putative new lineage of West Nile virus, Spain. Emerg Infect Dis. 2010; 16(3): 549-552.
41. Pesko KN, Ebel GD. West Nile virus population genetics and evolution. Infect Genet Evol. 2012; 12(2): 181-190.
42. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E. West Nile virus: biology, transmission, and human infection. Clin Microbiol Rev. 2012; 25(4): 635-648.
43. Farajollahi A, Fonseca DM, Kramer LD, Marm Kilpatrick A. "Bird biting" mosquitoes and human disease: a review of the role of Culex pipiens complex mosquitoes in epidemiology. Infect Genet Evol. 2011; 11(7): 1577-1585.
44. Allan BF, Langerhans RB, Ryberg WA, et al. Ecological correlates of risk and incidence of West Nile virus in the United States. Oecologia. 2009; 158(4): 699-708.
45. Ezenwa VO, Milheim LE, Coffey MF, Godsey MS, King RJ, Guptill SC. Land cover variation and West Nile virus prevalence: patterns, processes, and implications for disease control. Vector Borne Zoonotic Dis. 2007; 7(2): 173-180.
46. Turell MJ, Dohm DJ, Sardelis MR, Oguinn ML, Andreadis TG, Blow JA. An update on the potential of north American mosquitoes (Diptera: Culicidae) to transmit West Nile Virus. J Med Entomol. 2005; 42(1): 57-62.
47. Turell MJ, O'Guinn ML, Dohm DJ, Jones JW. Vector competence of North American mosquitoes (Diptera: Culicidae) for West Nile virus. J Med Entomol. 2001; 38(2): 130-134.
48. Balenghien T, Fouque F, Sabatier P, Bicout DJ. Horse-, bird-, and human-seeking behavior and seasonal abundance of mosquitoes in a West Nile virus focus of southern France. J Med Entomol. 2006; 43(5): 936-946.
49. Muñoz J, Ruiz S, Soriguer R, et al. Feeding patterns of potential West Nile virus vectors in south-west Spain. PLoS One. 2012; 7(6): e39549.
50. Kilpatrick AM, LaDeau SL, Marra PP. Ecology of West Nile virus Transmission and its impact on birds in the western hemisphere. The Auk. 2007; 124(4): 1121-1136.
51. Komar N, Langevin S, Hinten S, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis. 2003; 9(3): 311-322.
52. Anderson JF, Andreadis TG, Vossbrinck CR, et al. Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science. 1999; 286(5448): 2331-2333.
53. Pealer LN, Marfin AA, Petersen LR, et al; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003; 349(13): 1236-1245.
54. Nett RJ, Kuehnert MJ, Ison MG, Orlowski JP, Fischer M, Staples JE. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis. 2012; 14(3): 268-277.
55. O'Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics. 2006; 117(3): e537-e545.
56. Venter M, Burt FJ, Blumberg L, Fickl H, Paweska J, Swanepoel R. Cytokine induction after laboratory-acquired West Nile virus infection. N Engl J Med. 2009; 360(12): 1260-1262.
57. Beasley DW, Li L, Suderman MT, Barrett AD. West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. Ann N Y Acad Sci. 2001; 951: 332-335.
58. Beasley DW, Davis CT, Whiteman M, Granwehr B, Kinney RM, Barrett AD. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004; (18): 35-41.
59. Lim SM, Koraka P, van Boheemen S, et al. Characterization of the mouse neuroinvasiveness of selected European strains of West Nile virus. PLoS One. 2013; 8(9): e74575.
60. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001; 358(9278): 261-264.
61. Solomon T. Flavivirus encephalitis. N Engl J Med. 2004; 351(4): 370-378.
62. Hubálek Z. Comparative symptomatology of West Nile fever. Lancet. 2001; 358(9278): 254-255.
63. Zou S, Foster GA, Dodd RY, Petersen LR, Stramer SL. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis. 2010; 202(9): 1354-1361.
64. Carson PJ, Borchardt SM, Custer B, et al. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis. 2012; 18(4): 684-686.
65. Kramer LD, Li J, Shi PY. West Nile virus. Lancet Neurol. 2007; 6(2): 171-181.
66. Bode AV, Sejvar JJ, Pape WJ, Campbell GL, Marfin AA. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006; 42(9): 1234-1240.
67. Danis K, Papa A, Theocharopoulos G, et al. Outbreak of West Nile virus infection in Greece, 2010. Emerg Infect Dis. 2011; 17(10): 1868-1872.
68. Téllez-Zenteno JF, Hunter G, Hernández-Ronquillo L, Haghir E. Neuroinvasive West Nile virus disease in Canada. The Saskatchewan experience. Can J Neurol Sci. 2013; 40(4): 580-584.
69. Leis AA, Stokic DS. Neuromuscular manifestations of West Nile virus infection. Front Neurol. 2012; 3: 37.
70. Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA. 2013; 310(3): 308-315.
71. Garg S, Jampol LM. Systemic and intraocular manifestations of West Nile virus infection. Surv Ophthalmol. 2005; 50(1): 3-13.
72. Khairallah M, Ben Yahia S, Ladjimi A, et al. Chorioretinal involvement in patients with West Nile virus infection. Ophthalmology. 2004; 111(11): 2065-2070.
73. Georges AJ, Lesbordes JL, Georges-Courbot MC, Meunier DMY, Gonzalez JP. Fatal hepatitis from West Nile virus. Ann Inst Pasteur Virol. 1987(2); 138: 237-244.
74. Perelman A, Stern J. Acute pancreatitis in West Nile Fever. Am J Trop Med Hyg. 1974; 23(6): 1150-1152.
75. Montgomery SP, Chow CC, Smith SW, Marfin AA, O'Leary DR, Campbell GL. Rhabdomyolysis in patients with West Nile encephalitis and meningitis. Vector Borne Zoonotic Dis. 2005; 5(3): 252-257.
76. Pergam SA, DeLong CE, Echevarria L, Scully G, Goade DE. Myocarditis in West Nile Virus infection. Am J Trop Med Hyg. 2006; 75(6): 1232-1233.
77. Smith RD, Konoplev S, DeCourten-Myers G, Brown T. West Nile virus encephalitis with myositis and orchitis. Hum Pathol. 2004; 35(2): 254-258.
78. Stewart RD, Bryant SN, Sheffield JS. West Nile virus infection in pregnancy. Case Rep Infect Dis. 2013; 2013: 351872.
79. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Nucleic acid testing for west nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis. 2006; 193(10): 1361-1364.
80. Murray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg. 2013; 89(5): 996-1000.
81. Papa A, Danis K, Athanasiadou A, Delianidou M, Panagiotopoulos T. Persistence of West Nile virus immunoglobulin M antibodies, Greece. J Med Virol. 2011; 83(10): 1857-1860.
82. Busch MP, Kleinman SH, Tobler LH, et al. Virus and antibody dynamics in acute west nile virus infection. J Infect Dis. 2008; 198(7): 984-993.
83. Busch MP, Tobler LH, Saldanha J, et al. Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion. 2005; 45(4): 492-499.
84. Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci. 2004; 31(2): 194-203.
85. Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008; 47(3): 303-327.
86. Kramer AH. Viral encephalitis in the ICU. Crit Care Clin. 2013; 29(3): 621-649.
87. Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009; 83(3): 214-227.
88. Baharuddin A, Hassan AA, Sheng GC, et al. Current approaches in antiviral drug discovery against the Flaviviridae family. Curr Pharm Des. Epub September 2, 2013.
89. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-264.
90. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-1444.
91. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013; 57(12): 1731-1741.
92. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis. 2002; 8(1): 107-108.
93. Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 2000; 182(4): 1214-1217.
94. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002; 55(1): 107-116.
95. Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004; 15(2): 101-109.
96. Loginova SIa, Borisevich SV, Pashchenko IuA, Bondarev VP. [Ribavirin prophylaxis and therapy of experimental West Nile fever]. Antibiot Khimioter. 2009; 54(11-12): 17-20. Russian.
97. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001; 7(4): 675-678.
98. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007; 6(12): 975-990.
99. Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J Leukoc Biol. 2002; 71(4): 565-581.
100. Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005; 79(21): 13350-13361.
101. Brooks TJ, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res. 1999; 41(1): 57-64.
102. Rodríguez-Pulido M, Martín-Acebes MA, Escribano-Romero E, et al. Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts. PLoS One. 2012; 7(11): e49494.
103. Kalil AC, Devetten MP, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis. 2005; 40(5): 764-766.
104. Chan-Tack KM, Forrest G. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis. 2005; 37(11-12): 944-946.
105. Lewis M, Amsden JR. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy. 2007; 27(3): 455-458.
106. Jackson AC. Therapy of West Nile virus infection. Can J Neurol Sci. 2004; 31(2): 131-134.
107. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis. 2003; 188(1): 1-4.
108. Morrey JD, Siddharthan V, Olsen AL, et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis. 2006; 194(9): 1300-1308.
109. Ben-Nathan D, Gershoni-Yahalom O, Samina I, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis. 2009; 9: 18.
110. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis. 1974; 130(6): 634-641.
111. Levi ME, Quan D, Ho JT, Kleinschmidt-Demasters BK, Tyler KL, Grazia TJ. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010; 24(2): 223-228.
112. Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis. 2011; 13(3): 312-317.
113. Haley M, Retter AS, Fowler D, Gea-Banacloche J, O'Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis. 2003; 37(6): e88-e90.
114. National Institute of Allergy and Infectious Diseases (NIAID). A phase I/II randomized, placebo-controlled trial to assess the safety and efficacy of intravenous immunoglobulin G (OMR-IGG-AM) containing high anti-West Nile virus antibody titers in patients with, or at high risk for progression to West Nile virus (WNV) encephalitis and/or myelitis. Available from: http://www. clinicaltrials. gov/show/NCT00068055. NLM identifier: NCT00068055. Accessed March 20, 2014.
115. Morelli MC, Sambri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis. 2010; 51(4): e34-e37.
116. Goodyer LI, Croft AM, Frances SP, et al. Expert review of the evidence base for arthropod bite avoidance. J Travel Med. 2010; 17(3): 182-192.
117. Debboun M, Strickman D. Insect repellents and associated personal protection for a reduction in human disease. Med Vet Entomol. 2013; 27(1): 1-9.
118. Goodyer L, Behrens RH. Short report: The safety and toxicity of insect repellents. Am J Trop Med Hyg. 1998; 59(2): 323-324.
119. Gibney KB, Colborn J, Baty S, et al. Modifiable risk factors for West Nile virus infection during an outbreak-Arizona, 2010. Am J Trop Med Hyg. 2012; 86(5): 895-901.
120. Kilpatrick AM, Pape WJ. Predicting human West Nile virus infections with mosquito surveillance data. Am J Epidemiol. 2013; 178(5): 829-835.
121. Komar N. West Nile virus surveillance using sentinel birds. Ann N Y Acad Sci. 2001; 951: 58-73.
122. Cito F, Narcisi V, Danzetta ML, et al. Analysis of surveillance systems in place in European mediterranean countries for West Nile Virus (WNV) and Rift Valley Fever (RVF). Transbound Emerg Dis. 2013; 60(Suppl S2): S40-S44.
123. Dohm DJ, O'Guinn ML, Turell MJ. Effect of environmental temperature on the ability of Culex pipiens (Diptera: Culicidae) to transmit West Nile virus. J Med Entomol. 2002; 39(1): 221-225.
124. Beasley DW, Barrett AD, Tesh RB. Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done? Antiviral Res. 2013; 99(1): 1-5.
125. Paz S, Semenza JC. Environmental drivers of West Nile fever epidemiology in Europe and Western Asia-a review. Int J Environ Res Public Health. 2013; 10(8): 3543-3562.
126. Carney RM, Ahearn SC, McConchie A, et al. Early warning system for West Nile virus risk areas, California, USA. Emerg Infect Dis. 2011; 17(8): 1445-1454.
127. Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis. 2004; 23(3): 147-156.
128. Morin CW, Comrie AC. Regional and seasonal response of a West Nile virus vector to climate change. Proc Natl Acad Sci U S A. 2013; 110(39): 15620-15625.
129. Chevalier V, Tran A, Durand B. Predictive modeling of West Nile virus transmission risk in the Mediterranean Basin: how far from landing? Int J Environ Res Public Health. 2014; 11(1): 67-90.
130. Beasley DW. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy. 2011; 3(2): 269-285.
131. Durbin AP, Wright PF, Cox A, et al. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine. 2013; 31(48): 5772-5777.
132. Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults $50 years of age. Vaccine. 2012; 30(47): 6656-6664.
133. Ledgerwood JE, Pierson TC, Hubka SA, et al; VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011; 203(10): 1396-1404.
134. Kaiser J. Outbreak pattern stymies vaccine work. Science. 2012; 337(6098): 1030.